Plasma Concentrations of Tranexamic Acid in Postpartum Women After Oral Administration
- PMID: 32168220
- PMCID: PMC7098443
- DOI: 10.1097/AOG.0000000000003750
Plasma Concentrations of Tranexamic Acid in Postpartum Women After Oral Administration
Abstract
Objective: To evaluate the pharmacokinetics of tranexamic acid after oral administration to postpartum women.
Methods: We conducted a single-center pharmacokinetic study at Teaching Hospital-Jaffna, Sri Lanka, on 12 healthy postpartum women who delivered vaginally. After oral administration of 2 g of immediate-release tranexamic acid 1 hour after delivery, pharmacokinetic parameters were measured on plasma samples at 0, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, and 12 hours. Plasma tranexamic acid concentrations were determined by high-performance liquid chromatography. The outcome measures were maximum observed plasma concentration, time to maximum plasma concentration, time to reach effective plasma concentration, time period effective serum concentration lasted, area under the curve for drug concentration, and half-life of tranexamic acid.
Results: The mean maximum observed plasma concentration was 10.06 micrograms/mL (range 8.56-12.22 micrograms/mL). The mean time to maximum plasma concentration was 2.92 hours (range 2.5-3.5 hours). Mean time taken to reach the effective plasma concentration of 5 micrograms/mL and the mean time this concentration lasted were 0.87 hours and 6.73 hours, respectively. Duration for which plasma tranexamic acid concentration remained greater than 5 micrograms/mL was 5.86 hours. Half-life was 1.65 hours. Area under the curve for drug concentration was 49.16 micrograms.h/mL (range 43.75-52.69 micrograms.h/mL).
Conclusion: Clinically effective plasma concentrations of tranexamic acid in postpartum women may be achieved within 1 hour of oral administration. Given the promising pharmacokinetic properties, we recommend additional studies with larger sample sizes to investigate the potential of oral tranexamic acid for the treatment or prophylaxis of postpartum hemorrhage.
Figures
Similar articles
-
Optimal use of intravenous tranexamic acid for hemorrhage prevention in pregnant women.Am J Obstet Gynecol. 2021 Jul;225(1):85.e1-85.e11. doi: 10.1016/j.ajog.2020.11.035. Epub 2020 Nov 26. Am J Obstet Gynecol. 2021. PMID: 33248975 Free PMC article.
-
Pharmacokinetics of tranexamic acid after intravenous, intramuscular, and oral routes: a prospective, randomised, crossover trial in healthy volunteers.Br J Anaesth. 2022 Mar;128(3):465-472. doi: 10.1016/j.bja.2021.10.054. Epub 2022 Jan 5. Br J Anaesth. 2022. PMID: 34998508 Clinical Trial.
-
Tranexamic acid for the treatment of postpartum hemorrhage: a cost-effectiveness analysis.Am J Obstet Gynecol MFM. 2022 May;4(3):100588. doi: 10.1016/j.ajogmf.2022.100588. Epub 2022 Feb 3. Am J Obstet Gynecol MFM. 2022. PMID: 35124299
-
Tranexamic acid for the prevention of postpartum hemorrhage in women undergoing cesarean delivery: an updated meta-analysis.Am J Obstet Gynecol. 2022 Apr;226(4):510-523.e22. doi: 10.1016/j.ajog.2021.09.025. Epub 2021 Sep 25. Am J Obstet Gynecol. 2022. PMID: 34582795 Review.
-
AANA Journal Course: Update for Nurse Anesthetists-Part 5-Use of Tranexamic Acid in Preventing Postpartum Hemorrhage.AANA J. 2016 Dec;84(6):427-438. AANA J. 2016. PMID: 28235177 Review.
Cited by
-
Tranexamic acid in a mouse model of cerebral amyloid angiopathy: setting the stage for a novel stroke treatment approach.Res Pract Thromb Haemost. 2023 Aug 9;7(6):102166. doi: 10.1016/j.rpth.2023.102166. eCollection 2023 Aug. Res Pract Thromb Haemost. 2023. PMID: 37694270 Free PMC article.
-
Uptake of orally administered tranexamic acid in women during active labor: A pilot intervention study on prophylactic treatment of postpartum hemorrhage.Acta Obstet Gynecol Scand. 2025 Jul;104(7):1347-1356. doi: 10.1111/aogs.15129. Epub 2025 Apr 24. Acta Obstet Gynecol Scand. 2025. PMID: 40270358 Free PMC article. Clinical Trial.
-
Optimal use of intravenous tranexamic acid for hemorrhage prevention in pregnant women.Am J Obstet Gynecol. 2021 Jul;225(1):85.e1-85.e11. doi: 10.1016/j.ajog.2020.11.035. Epub 2020 Nov 26. Am J Obstet Gynecol. 2021. PMID: 33248975 Free PMC article.
-
Alternative routes to intravenous tranexamic acid for postpartum hemorrhage: A systematic search and narrative review.Int J Gynaecol Obstet. 2022 Jun;158 Suppl 1(Suppl 1):40-45. doi: 10.1002/ijgo.14201. Int J Gynaecol Obstet. 2022. PMID: 35762806 Free PMC article. Review.
-
Concentration-effect relationship for tranexamic acid inhibition of tissue plasminogen activator-induced fibrinolysis in vitro using the viscoelastic ClotPro® TPA-test.Br J Anaesth. 2024 Feb;132(2):343-351. doi: 10.1016/j.bja.2023.09.027. Epub 2023 Nov 3. Br J Anaesth. 2024. PMID: 37925268 Free PMC article.
References
-
- Alkema L, Chou D, Hogan D, Zhang S, Moller AB, Gemmill A, et al. Global, regional, and national levels and trends in maternal mortality between 1990 and 2015, with scenario-based projections to 2030: a systematic analysis by the UN Maternal Mortality Estimation Inter-Agency Group. Lancet 2016;387:462–74. - PMC - PubMed
-
- Trends in maternal mortality: 1990 to 2015: estimates by WHO, UNICEF, UNFPA, World Bank Group and the United Nations Population Division. Geneva (Switzerland): World Health Organization; 2015.
-
- WHO recommendation on tranexamic acid for the treatment of postpartum haemorrhage. Geneva, Switzerland: World Health Organization; 2017. - PubMed
-
- CRASH-2 Collaborators. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomized, placebo-controlled trial. Lancet 2010;376:23–32. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical